Genetic Factors in Giant Cell Arteritis and Polymyalgia Rheumatica

Chapter
First Online:

Abstract

The etiopathogenesis of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) remains unknown, although genetic, autoimmune and environmental factors have been implicated. Evidence points to a genetic predisposition in these syndromes. GCA and PMR are more frequent in Caucasians, especially in the countries of northern Europe and in some regions of the United States, in those with Scandinavian ancestry [1, 2]. Several cases of familial aggregation of GCA and PMR have been also reported [3, 4], and HLA typing studies have shown a consistent association of both syndromes with certain alleles of the HLA system [5].

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum. 1994;37:1007–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in Northern Italy. Arthritis Rheum. 1991;34:351–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Bartolome MJ, Martínez-Taboda VM, Lopez-Hoyos M, et al. Familial aggregation of polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol. 2001;19:259–64.PubMedGoogle Scholar
  4. 4.
    Fietta P, Manganelli P, Zanetti A, Neri TM. Familial giant cell arteritis and polymyalgia rheumatica. Aggregation in 2 families. J Rheumatol. 2002;29:1551–5.PubMedGoogle Scholar
  5. 5.
    Bošák V. HLA-systém a jeho význam v reumatológii. In: Klinická reumatológia, editor. 1. slov. vyd. Martin: Osveta; 2000. p. 127–44.Google Scholar
  6. 6.
    Rosenthal M, Mullen W, Albert ED, et al. HL-A antigens in 15 patients with polymyalgia rheumatica and in 1142 controls. N Engl J Med. 1975;292:595.PubMedGoogle Scholar
  7. 7.
    Gonzalez-Guy MA. Genetic epidemiology of GCA and PMR. Arthritis Res. 2001;3:1554–7.Google Scholar
  8. 8.
    Weyand MC, Goronzy JJ. Molecular approaches toward pathologic mechanism in GCA and Takayasu’s arteritis. Curr Opin Rheumatol. 1995;7:30–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Gonzalez-Guy MA, Hajeer AH, Dababneh A, et al. Seronegative rheumatoid arthritis in elderly and PMR have similar patterns of HLA association. J Rheumatol. 2001;28:122–5.Google Scholar
  10. 10.
    Martínez-Taboda VM, Bartolome J, Lopez-Hoyos M, et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum. 2004;34:454–64.CrossRefPubMedGoogle Scholar
  11. 11.
    Pease CT, Haugeberg G, Morgan AW, et al. Diagnostic late onset rheumatoid arthritis, polymyalgia rheumatica and temporal arteritis in patients presenting polymyalgic symptoms. J Rheumatol. 2005;32:1043–6.PubMedGoogle Scholar
  12. 12.
    Reviron D, Foutrier C, Gula S, et al. DRB1 alleles in PMR and rheumatoid arthritis in southern France. Eur J Immunogenet. 2001;28:83–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRB1 alleles associated with PMR in northern Italy: correlation with disease severity. Ann Rheum Dis. 1999;58:303–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gonzales-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of diseases susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48.CrossRefGoogle Scholar
  15. 15.
    Amoli MM, Gonzales-Gay MA, Zeggini E, et al. Epistatic interaction between HLA-DRB1 and interleukin 4, but not interferon-gamma, increased susceptibility to giant cell arteritis. J Rheumatol. 2004;31:2413–7.PubMedGoogle Scholar
  16. 16.
    Gonzalez-Guy MA, Garcia-Porrua C, Hajeer AH, et al. HLA-DRB1*04 may be a marker of severity in GCA. Ann Rheum Dis. 2000;59:574–5.CrossRefGoogle Scholar
  17. 17.
    Dababneh A, Gonzales-Gay MA, Garcia-Porrua C, et al. GCA and PMR can be differentiated by distinct patterns of HLA class II association. J Rheumatol. 1998;25:2140–5.PubMedGoogle Scholar
  18. 18.
    Bošák V, Tuchyňová A, Rovenský J, Mičeková D. Immunogenetic study in Slovak patients with polymyalgia rheumatica and giant cell arteritis. Wien Med Wochenschr. 2002;152(Suppl 112):9.Google Scholar
  19. 19.
    Carmona FD, González-Gay MA, Martín J. Genetic component of giant cell arteritis. Rheumatology (Oxford). 2014;53:6–18.CrossRefGoogle Scholar
  20. 20.
    Gregersen PK. Susceptibility genes for rheumatoid arthritis: a rapidly expanding harvest. Bull NYU Hosp Jt Dis. 2010;68:179–82.PubMedGoogle Scholar
  21. 21.
    Carmona FD, Mackie SL, Martín JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet. 2015;96:565–80.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ly KH, Regent A, Tamby MC, et al. Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev. 2010;9:635–45.CrossRefPubMedGoogle Scholar
  23. 23.
    Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology. 2004;43:294–301.CrossRefPubMedGoogle Scholar
  24. 24.
    Mattey DL, Hajeer AH, Dababneh A, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum. 2000;43:1749–55.CrossRefPubMedGoogle Scholar
  25. 25.
    Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Weyand CM, Tetzlaff N, Bjornsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum. 1997;40:19–26.CrossRefPubMedGoogle Scholar
  27. 27.
    Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol. 2004;22:S18–20.PubMedGoogle Scholar
  28. 28.
    Amoli MM, Gonzalez-Gay MA, Zeggini E, et al. Epistatic interactions between HLA-DRB1 and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis. J Rheumatol. 2004;31:2413–7.PubMedGoogle Scholar
  29. 29.
    Boiardi L, Casali B, Farnetti E, et al. Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum. 2006;54:4011–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Rueda B, Roibas B, Martin J, et al. Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in northwestern Spain. J Rheumatol. 2007;34:1535–9.PubMedGoogle Scholar
  31. 31.
    Salvarani C, Casali B, Farnetti E, et al. Interleukin-6 promoter polymorphism at position −174 in giant cell arteritis. J Rheumatol. 2005;32:2173–7.PubMedGoogle Scholar
  32. 32.
    Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. IL-6 promoter polymorphism at position −174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol. 2002;20:179–84.PubMedGoogle Scholar
  33. 33.
    Enjuanes A, Benavente Y, Hernandez-Rodriguez J, et al. Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology. 2012;51:841–51.CrossRefPubMedGoogle Scholar
  34. 34.
    Nabili S, Bhatt P, Roberts F, et al. Local expression of IL-18 in the temporal artery does not correlate with clinical manifestations of giant cell arteritis. Neuro-Ophthalmology. 2008;32:3–6.CrossRefGoogle Scholar
  35. 35.
    Palomino-Morales RJ, Vazquez-Rodriguez TR, Torres O, et al. Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis Res Ther. 2010;12:R51.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ellingsen T, Elling P, Olson A, et al. Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2000;59:775–80.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–7.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992;90:772–9.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Amoli MM, Salway F, Zeggini E, et al. MCP-1 gene haplotype association in biopsy proven giant cell arteritis. J Rheumatol. 2005;32:507–10.PubMedGoogle Scholar
  40. 40.
    Pulsatelli L, Meliconi R, Boiardi L, et al. Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol. 1998;16:263–8.PubMedGoogle Scholar
  41. 41.
    Makki RF, al Sharif F, Gonzalez-Gay MA, et al. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin Exp Rheumatol. 2000;18:391–3.PubMedGoogle Scholar
  42. 42.
    Rodriguez-Rodriguez L, Carmona FD, Castaneda S, et al. Role of rs1343151 IL23R and rs3790567 IL12RB2 polymorphisms in biopsy-proven giant cell arteritis. J Rheumatol. 2011;38:889–92.CrossRefPubMedGoogle Scholar
  43. 43.
    Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986;137:245–54.PubMedGoogle Scholar
  44. 44.
    Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301–14.CrossRefPubMedGoogle Scholar
  45. 45.
    Cid MC, Cebrian M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum. 2000;43:184–94.CrossRefPubMedGoogle Scholar
  46. 46.
    Coll-Vinent B, Vilardell C, Font C, et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis. 1999;58:189–92.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22.PubMedGoogle Scholar
  48. 48.
    Meliconi R, Pulsatelli L, Dolzani P, et al. Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum. 2000;43:2472–80.CrossRefPubMedGoogle Scholar
  49. 49.
    Baldini M, Maugeri N, Ramirez GA, et al. Selective upregulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum. 2012;64:854–65.CrossRefPubMedGoogle Scholar
  50. 50.
    Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298(Pt 2):249–58.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Gonzalez-Gay MA, Oliver J, Sanchez E, et al. Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol. 2005;32:2178–82.PubMedGoogle Scholar
  52. 52.
    Amoli MM, Garcia-Porrua C, Llorca J, et al. Endothelial nitric oxide synthase haplotype associations in biopsy proven giant cell arteritis. J Rheumatol. 2003;30:2019–122.PubMedGoogle Scholar
  53. 53.
    Salvarani C, Casali B, Nicoli D, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum. 2003;48:3219–23.CrossRefPubMedGoogle Scholar
  54. 54.
    Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–62.PubMedGoogle Scholar
  55. 55.
    Sorbi D, French DL, Nuovo GJ, et al. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum. 1996;39:1747–53.CrossRefPubMedGoogle Scholar
  56. 56.
    Nikkari ST, Hoyhtya M, Isola J, et al. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol. 1996;149:1427–33.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Tomita T, Imakawa K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in giant cell arteritis: an immunocytochemical study. Pathology. 1998;30:40–50.CrossRefPubMedGoogle Scholar
  58. 58.
    Rodriguez-Pla A, Bosch-Gil JA, Rossello-Urgell J, et al. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation. 2005;112:264–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Segarra M, Garcia-Martinez A, Sanchez M, et al. Gelatinase expression and proteolytic activity in giant cell arteritis. Ann Rheum Dis. 2007;66:1429–35.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Rodriguez-Pla A, Beaty TH, Savino PJ, et al. Association of a nonsynonymous single-nucleotide polymorphism of matrix metalloproteinase 9 with giant cell arteritis. Arthritis Rheum. 2008;58:1849–53.CrossRefPubMedGoogle Scholar
  61. 61.
    Palomino-Morales R, Torres O, Vazquez-Rodriguez TR, et al. Association between toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol. 2009;36:1501–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Alvarez-Rodriguez L, Lopez-Hoyos M, Beares I, et al. Lack of association between Toll-like receptor 4 gene polymorphisms and giant cell arteritis. Rheumatology. 2011;50:1562–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Boiardi L, Casali B, Farnetti E, et al. Toll-like receptor 4 (TLR4) gene polymorphisms in giant cell arteritis. Clin Exp Rheumatol. 2009;27:S40–4.PubMedGoogle Scholar
  64. 64.
    Alvarez-Rodriguez L, Munoz Cacho P, Lopez-Hoyos M, et al. Toll-like receptor 4 gene polymorphism and giant cell arteritis susceptibility: a cumulative meta-analysis. Autoimmun Rev. 2011;10:790–2.CrossRefPubMedGoogle Scholar
  65. 65.
    Morgan AW, Robinson JI, Barrett JH, et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther. 2006;8:R109.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med. 1980;93:480–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Nambi V. The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep. 2005;7:127–31.CrossRefPubMedGoogle Scholar
  68. 68.
    Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–42.CrossRefPubMedGoogle Scholar
  69. 69.
    Piedrafita FJ, Molander RB, Vansant G, et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412–20.CrossRefPubMedGoogle Scholar
  70. 70.
    Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. Proc Natl Acad Sci U S A. 1995;92:8229–33.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Salvarani C, Casali B, Farnetti E, et al. ˗463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis. Ann Rheum Dis. 2008;67:485–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Cortes A, Brown MA. Promise and pitfalls of the immunochip. Arthritis Res Ther. 2011;13:101.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, et al. Spanish Scleroderma Group. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet. 2014;94:47–61.Google Scholar
  74. 74.
    Duhaut P, Bosshard S, Ducroix JP. Is giant cell arteritis an infectious disease? Biological and epidemiological evidence. Presse Med. 2004;33:1403–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol. 1996;23:112–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Faculty of Health Studies and Social WorkTrnava UniversityTrnavaSlovak Republic

Personalised recommendations